Journal of the American Society of Nephrology, Vol 2, 1405-1416, Copyright © 1992 by American Society of Nephrology

REGULAR ARTICLES

Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration

A Besarab, KK Flaharty, AJ Erslev, JB McCrea, PH Vlasses, F Medina, J Caro and E Morris
Department of Medicine, Jefferson Medical College, Philadelphia, PA.

The clinical pharmacology of human recombinant erythropoietin (epoetin) was studied in order to compare the effectiveness of various routes and dosing schedules in dialysis patients. Thirty-six patients received epoetin beta three times a week i.v. for at least 12 wk. The mean dose needed to achieve target hemoglobin was 225 +/- 36 U/kg per week (median dose, 180 U/kg per week). Twenty-eight of 36 patients who were converted to a once-a-week i.v. schedule increased their requirements to 429 +/- 50 U/kg per week in order to maintain a target hematocrit of 33 to 40 vol%. Twelve of 28 patients could maintain their target hematocrit when dosed once a week s.c. at 84 +/- 10 U/kg. The other 16 patients required 137 +/- 15 U/kg per week divided into two doses. In the entire group of 28 patients, the weekly requirement for epoetin was reduced by 50% when the s.c. route was used two or three times a week. Pharmacokinetic studies performed during chronic therapy indicated rapid clearance of erythropoietin (t1/2 of 6.8 +/- 0.3 h). Single i.v. doses greater than 150 U/kg were required to increase basal erythropoietin by 30 mU/mL at 44 h postdosing. With s.c. dosing, such increments in erythropoietin levels frequently persisted beyond 60 h because of prolonged and slow absorption. Pharmacokinetic simulations in conjunction with clinical correlation of the erythropoietic response suggest that the duration that the erythropoietin levels are maintained, and not the absolute peaks, is the primary determinant of efficacy. This may result from nonlinearity in the dose response. Pharmacokinetic simulation also indicated that i.v. dosing could not maintain adequate interdialytic erythropoietin levels, whereas s.c. dosing could. Cost analysis indicated that the use of s.c. dosing two or three times a week at an average total weekly dose of 110 to 120 U/kg is effective treatment of anemia in most dialysis patients.

This article has been cited by other articles:

				Y.-W. Fang and C.-H. Chang SUBCUTANEOUS ADMINISTRATION OF DARBEPOETIN ALFA EFFECTIVELY MAINTAINS HEMOGLOBIN CONCENTRATIONS AT EXTENDED DOSE INTERVALS IN PERITONEAL DIALYSIS PATIENTS Perit. Dial. Int., March 1, 2009; 29(2): 199 - 203. [Abstract] [Full Text] [PDF]

				J. Bommer, G. Asmus, M. Wenning, and G. Bommer A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study Nephrol. Dial. Transplant., December 1, 2008; 23(12): 4002 - 4008. [Abstract] [Full Text] [PDF]

				F. Carrera, A. Disney, and M. Molina Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_4): iv19 - iv30. [Abstract] [Full Text] [PDF]

				L. M Moist, N. Muirhead, L. D Wazny, K. L Gallo, A P. Heidenheim, and A. A House Erythropoietin Dose Requirements When Converting from Subcutaneous to Intravenous Administration Among Patients on Hemodialysis Ann. Pharmacother., February 1, 2006; 40(2): 198 - 203. [Abstract] [Full Text] [PDF]

				J. W. Galliford, R. Malasana, and K. Farrington Switching from subcutaneous to intravenous erythropoietin {alpha} in haemodialysis patients requires a major dose increase Nephrol. Dial. Transplant., September 1, 2005; 20(9): 1956 - 1962. [Abstract] [Full Text] [PDF]

				L. M. Vercaigne, D. M. Collins, and S. B. Penner Conversion From Subcutaneous to Intravenous Erythropoietin in a Hemodialysis Population J. Clin. Pharmacol., August 1, 2005; 45(8): 895 - 900. [Abstract] [Full Text] [PDF]

				G. Justice, J. F. Kessler, J. Jadeja, L. Campos, J. Weick, C.-F. Chen, A. C. Heatherington, and R. G. Amado A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia Ann. Onc., July 1, 2005; 16(7): 1192 - 1198. [Abstract] [Full Text] [PDF]

				R. Ramakrishnan, W. K. Cheung, M. C. Wacholtz, N. Minton, and W. J. Jusko Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin After Single and Multiple Doses in Healthy Volunteers J. Clin. Pharmacol., September 1, 2004; 44(9): 991 - 1002. [Abstract] [Full Text] [PDF]

				I. C. Macdougall, J. Matcham, and S. J. Gray Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis Nephrol. Dial. Transplant., March 1, 2003; 18(3): 576 - 581. [Abstract] [Full Text] [PDF]

				F. Locatelli, B. Canaud, F. Giacardy, A. Martin-Malo, N. Baker, and J. Wilson Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo) Nephrol. Dial. Transplant., February 1, 2003; 18(2): 362 - 369. [Abstract] [Full Text] [PDF]

				C. H. Jones, L. Ridley, D. Richardson, and L. Weiss Which EPO dose per week? Nephrol. Dial. Transplant., October 1, 2002; 17(10): 1855 - 1855. [Full Text] [PDF]

				D.-C. Tarng and T.-P. Huang Determinants of circulating soluble transferrin receptor level in chronic haemodialysis patients Nephrol. Dial. Transplant., June 1, 2002; 17(6): 1063 - 1069. [Abstract] [Full Text] [PDF]

				A. BESARAB, N. AMIN, M. AHSAN, S. E. VOGEL, G. ZAZUWA, S. FRINAK, J. J. ZAZRA, J. V. ANANDAN, and A. GUPTA Optimization of Epoetin Therapy with Intravenous Iron Therapy in Hemodialysis Patients J. Am. Soc. Nephrol., March 1, 2000; 11(3): 530 - 538. [Abstract] [Full Text] [PDF]

				B. Jeren-Strujic, V. Raos, T. Jeren, S. Horvatin-Godler, and B. Jeren-Strujic Morphologic and Functional Changes of Left Ventricle in Dialyzed Patients After Treatment with Recombinant Human Erythropoietin (r-HuEPO) Angiology, February 1, 2000; 51(2): 131 - 139. [Abstract] [PDF]

				J. S. Kaufman, D. J. Reda, C. L. Fye, D. S. Goldfarb, W. G. Henderson, J. G. Kleinman, C. A. Vaamonde, and The Department of Veterans Affairs Cooperative Stu Subcutaneous Compared with Intravenous Epoetin in Patients Receiving Hemodialysis N. Engl. J. Med., August 27, 1998; 339(9): 578 - 583. [Abstract] [Full Text] [PDF]

				L. T. Goodnough, T. G. Monk, and G. L. Andriole Erythropoietin Therapy N. Engl. J. Med., March 27, 1997; 336(13): 933 - 938. [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673